Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Medical cannabis 

One in ten hospital trusts have been asked to approve unlicensed cannabis-based medicinal prescriptions

Exclusive: Around 10% of hospital trusts responding to a freedom of information request said they had received requests for prescriptions of unlicensed cannabis-based medical products since 1 November 2018.

medical cannabis

Source: Shutterstock.com

Cannabis for medical use was legalised on 1 November 2018

Around 10% of hospital trusts have received requests for prescriptions of unlicensed cannabis-based medical products, according to a freedom of information request submitted by The Pharmaceutical Journal.

Trusts were asked how many requests for prescriptions of unlicensed cannabis-based medical products (CBMPs) had been made though their trust’s drugs and therapeutics committee (or similar approval process) since cannabis was legalised for medical use on 1 November 2018.

Of the 138 trusts that responded with figures, 13 said requests had been made. Nine of these trusts had approved requests, three had rejected them and one was pending a descision at the time of writing.

In four of these trusts, multiple requests had been made. One trust had approved eight of these requests, with the others approving seven, six and five requests respectively.

Of the three that had rejected requests, differing reasons were given. In one case, the trust said they did not have a suitably registered prescriber; one trust said that it was not a specialist tertiary centre; and the third trust said the request was for Epidyolex (GW Pharma) and the case was not for one of the two conditions that this drug is approved for. 

National Institute for Health and Care Excellence (NICE) guidance produced in 2019 did not recommend CBMPs for chronic pain, and said that that more research was needed into the clinical effectiveness and cost-effectiveness of CBMPs in severe epilepsy.

Mike Barnes, a consultant neurologist and chair of the Medical Cannabis Clinicians Society, said that it was good news that nine trusts had approved requests for full-spectrum cannabis products, although he added: “If you ask for unlicensed medicines, some trusts hide behind the fact that they’ve been prescribing the two licensed cannabis products, Sativex [GW Pharma] and Epidyolex. There’s nothing wrong with that, but they’re not full-spectrum products, for which there are some — not many, but some — ongoing prescriptions”.

Barnes went on to say that “bearing in mind there are 1.4 million people in the UK who use cannabis for medical purposes, there’s rather a lot to go, still”.

A Care Quality Commission report published in July 2020 found that less than 10% of the CBMPs prescribed to patients in 2019 came from NHS prescriptions. The report said that in 2019, 259 CBMP items had been prescribed privately, while just 18 items had been prescribed through the NHS in the same period. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208544

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.